Keywords: merck, kgaa, forging, ahead, erbitux, germany, success

Merck KGaA forging ahead with Erbitux

Article | 05 August 2002

Print This

For Germany's Merck KGaA, the success of Erbitux (cetuximab), for whichit holds development and marketing rights outside North America, is ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in